New study in skin cancer

30th June 2022

SamanTree Medical, a medical technology company dedicated to supporting clinicians in making better intraoperative decisions and improving outcomes in cancer surgery, has announced the release of clinical data demonstrating the potential of its Histolog® Scanner in Mohs surgery. The study sheds new light on the Histolog Scanner's performance in supporting dermatologists and the potential benefits it can offer patients. According to the study, the Histolog Scanner has a sensitivity of over 80% and a specificity of 100% for detecting basal cell carcinoma (BCC). The study also highlights the significant time savings that the Histolog Scanner can provide compared to standard frozen section analysis.

"We are thrilled to see this study published in SKIN: The Journal of Cutaneous Medicine," commented Oleg Svanidze, CMO of SamanTree Medical. "The results underscore the potential of the Histolog Scanner, which offers greater flexibility with different tissue types compared to existing techniques, while also delivering high-resolution images and exceptional performance."

The study is particularly relevant in the context of skin cancer treatment and has important implications for patients who previously had to wait for hours with an open wound for frozen section results. "Now, it takes only a matter of minutes," added Oleg Svanidze. The findings of the study demonstrate the potential of the Histolog Scanner to improve outcomes in Mohs surgery and to support dermatologists in making more informed decisions about patient care.